RSN 0402
Alternative Names: RSN-0402Latest Information Update: 30 Jul 2024
At a glance
- Originator Shenzhen Resproly Biopharmaceutical
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 11 Jul 2024 Phase-I clinical trials in Idiopathic pulmonary fibrosis in Australia (Inhalation) (In Volunteers) (NCT06482190)